Auction-Rate Securities Cover Headlines With Bristol-Myers Squibb Loss. The broader investment world is getting a crash-
course in the arcane world of
auction-rate securities as news of
Bristol-Myers Squibb's $275 million impairment charge on an investment of $811 in ARS hit the wires this week. (
See our
"Link of the Day" and the
Bloomberg article.)
Auctions began failing in August, causing these securities to turn into longer-term holdings and causing an exodus from the formerly $300 billion sector. Though just
2% ($6 billion) of the sector has had problems, ARS were already reeling from an accounting decision to classify them as non-cash holdings. Today'
s
Wall Street Journal article "Credit Woes Hit in Unlikley Places" says, "
Bristol-Myers, which has traded auction-rate securities for nine years, is hardly alone. CFO
Andrew Bonfield says his auditors,
Deloitte & Touche, tell him
they have around 70 clients who are dealing with issues like this." Other companies, like
3M and USAir, have taken smaller, similar charges. The
demise of ARS is one reason for
recent massive inflows into money market funds.